These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 8273369)

  • 1. [Interferon therapy in malignant melanoma].
    Kokoschka EM; Micksche M
    Wien Med Wochenschr; 1993; 143(16-17):441-2. PubMed ID: 8273369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant melanoma.
    Califano J; Nance M
    Facial Plast Surg Clin North Am; 2009 Aug; 17(3):337-48. PubMed ID: 19698915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
    Kirkwood JM; Tarhini AA
    Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
    Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
    Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
    Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant and palliative therapy of melanoma. Current status].
    Tilgen W
    Chirurg; 1994 Mar; 65(3):153-63. PubMed ID: 7514966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha].
    Bédane C; Le Brun V; Boulinguez S; Berdah JF; Bouyssou ML; Delpuget N; Bernard P; Tubiana-Mathieu N; Bonnetblanc JM
    Ann Dermatol Venereol; 1999 Feb; 126(2):142-6. PubMed ID: 10352829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Consensus conference. Follow-up of patients surgically treated for stage I melanoma].
    Ann Dermatol Venereol; 1995; 122(5):250-8. PubMed ID: 8572461
    [No Abstract]   [Full Text] [Related]  

  • 9. [Combined and complex treatment of patients with II-stage malignant skin melanoma using hyperthermia].
    Zhavrid EA; Fradkin SZ; Bezruchko VI; Firmanchuk AV; Proleskovskiĭ AK
    Vopr Onkol; 1986; 32(3):52-7. PubMed ID: 3962258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comment on the contribution by U. Beiteke et al. Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Second comment].
    Gefeller O; Kleeberg U; Kölmel KF
    Hautarzt; 1994 Mar; 45(3):191-2; author reply 193-4. PubMed ID: 8175352
    [No Abstract]   [Full Text] [Related]  

  • 12. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

  • 13. [Melanoma].
    Saida T
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1386-91. PubMed ID: 17033225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidisciplinary treatment of primary melanoma.
    Yao K; Balch G; Winchester DJ
    Surg Clin North Am; 2009 Feb; 89(1):267-81, xi. PubMed ID: 19186240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence of cutaneous malignant melanoma after more than 20 years.
    Bredgaard R; Lock-Andersen J
    J Plast Surg Hand Surg; 2011 Apr; 45(2):113-6. PubMed ID: 21504283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
    J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant therapy of malignant melanoma].
    Franke W; Neumann NJ; Ruzicka T; Schulte KW
    Praxis (Bern 1994); 2001 Feb; 90(8):301-6. PubMed ID: 11256332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The adjuvant therapy of malignant melanoma].
    Hauschild A; Sterry W
    Dtsch Med Wochenschr; 1992 Feb; 117(8):303-6. PubMed ID: 1537268
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.